Early Discharge After Primary Percutaneous Coronary Intervention

NCT ID: NCT01860079

Last Updated: 2016-04-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* When Primary percutaneous coronary intervention (PPCI) is performed expeditiously and at a high-volume centre, it is the optimal approach for ST elevation myocardial infarction (STEMI) . In contrast to the clarity of how to treat STEMI, there is no clear definition for when to discharge and which patient to discharge.
* An early discharge strategy may be desired by all parties (financial health care provider, treating physician, nurse, patient, patient's relatives)involved in STEMI.
* The main goal in our study is to test the hypothesis that an early discharge strategy within 48-56 hours in patients with successful PPCI is as safe as in those patients who stay longer (96-120 hours) as of a standard procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Primary percutaneous coronary intervention (PPCI) has become the optimal reperfusion strategy for ST elevation myocardial infarction (STEMI) when the procedure is performed expeditiously and at a high-volume centre.In contrast to the clarity of how to treat STEMI, there is no clear definition for when to discharge and which patient to discharge.
* It is conceivable to discharge patients with successful PPCI as early as possible, because a hospital stay longer than needed may create undesirable outcomes in terms of hospital infections, psychosocial reasons, adequate mobilization and patient comfort. In many tertiary centres with a busy PPCI programme insufficient bed capacity is an ongoing concern and threatens the continuous acceptance of new cases of acute infarctions. In addition, it has been indicated that an early discharge policy may lead to a substantial cost saving.
* Although much work has been done in developing and validating risk scores that identify low risk patients, data on the implementation of early discharge strategies have been quite limited There are 3 randomised trials investigating the possibility of early discharge after PPCI. However, certain limitations of these studies are preventing to implement an early discharge strategy in all-comers, particularly because of the underrepresentation of older patients in clinical trials. The verification of this policy is also needed in patients with multivessel disease. The first prospective randomized trial, the PAMI II,7 is partly obsolete as major changes have been made in PPCI with respect to devices and adjunctive medication. The other two randomized trials were single-center pilot studies with small number of patients.
* Therefore, the above mentioned literature information warrants to test the reproducibility of safety endpoints in a large scale multicenter trial, prior to application of the early discharge strategy in clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ST Elevation Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early discharge group

In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.

Group Type ACTIVE_COMPARATOR

early discharge

Intervention Type PROCEDURE

In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.

Standard discharge group

Patients who stay longer (96-120 hours) as of a standard procedure

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

early discharge

In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent and subsequent written agreement of a family member (confirming good social background)
* Acute STEMI, defined as \>30 minutes of continuous typical chest pain and ST-segment elevation ≥2 mm in two contiguous electrocardiography leads and /or left bundle branch block within 12 hours of symptom onset.
* Haemodynamically stable Angiographically
* Successful PPCI procedure (TIMI 2-3 flow and %\<20 residual stenosis) and an uneventful 24 hour follow up period
* Single epicardial artery to be treated
* Telephone contact between the patient and PCI center after discharge is available 24 hours daily

Exclusion Criteria

* Inability to consent
* Patients treated with thrombolytic agents for the index STEMI
* Cardiogenic shock,
* Stroke within a month,
* Signs of heart failure (Killip II-IV)
* Hypotension (\<100 mmHg SBP) persisting after PPCI
* Chest pain recurrence
* Clinically significant arrhythmia (requiring treatment) occurring \>6 hours after PPCI.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acibadem University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sevket Gorgulu, MD

Role: STUDY_CHAIR

Acıbadem University School of Medicine

Tugrul Norgaz, MD

Role: PRINCIPAL_INVESTIGATOR

Acıbadem University School of Medicine

Sinan Dagdelen, MD

Role: PRINCIPAL_INVESTIGATOR

Acıbadem University School of Medicine

Nevzat Uslu, MD

Role: PRINCIPAL_INVESTIGATOR

Mehmet Akif Ersoy Education and Training Hospital

Aydin Yildirim, MD

Role: PRINCIPAL_INVESTIGATOR

Siyami Ersek Educational and Training Hospital

Ali Buturak, MD,

Role: PRINCIPAL_INVESTIGATOR

Acıbadem University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Acibadem University

Istanbul, , Turkey (Türkiye)

Site Status

Mehmet Akif Ersoy Education and Training Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Siyami Ersek Education and Training Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van 't Hof AW, Suryapranata H. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999 Nov 4;341(19):1413-9. doi: 10.1056/NEJM199911043411901.

Reference Type BACKGROUND
PMID: 10547403 (View on PubMed)

Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 Jan 4;361(9351):13-20. doi: 10.1016/S0140-6736(03)12113-7.

Reference Type BACKGROUND
PMID: 12517460 (View on PubMed)

Boersma E; Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006 Apr;27(7):779-88. doi: 10.1093/eurheartj/ehi810. Epub 2006 Mar 2.

Reference Type BACKGROUND
PMID: 16513663 (View on PubMed)

Laarman GJ, Dirksen MT. Early discharge after primary percutaneous coronary intervention. Heart. 2010 Apr;96(8):584-7. doi: 10.1136/hrt.2009.171363. Epub 2009 Sep 23.

Reference Type BACKGROUND
PMID: 19778921 (View on PubMed)

Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson ED, Armstrong PW, Van de Werf F, White HD, Topol EJ, Mark DB. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med. 2000 Mar 16;342(11):749-55. doi: 10.1056/NEJM200003163421101.

Reference Type BACKGROUND
PMID: 10717009 (View on PubMed)

Topol EJ, Burek K, O'Neill WW, Kewman DG, Kander NH, Shea MJ, Schork MA, Kirscht J, Juni JE, Pitt B. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med. 1988 Apr 28;318(17):1083-8. doi: 10.1056/NEJM198804283181702.

Reference Type BACKGROUND
PMID: 3281014 (View on PubMed)

Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, Balestrini C, Stone G, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Sachs D, Grines LL, O'Neill W. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998 Apr;31(5):967-72. doi: 10.1016/s0735-1097(98)00031-x.

Reference Type BACKGROUND
PMID: 9561995 (View on PubMed)

Jirmar R, Widimsky P, Capek J, Hlinomaz O, Groch L. Next day discharge after successful primary angioplasty for acute ST elevation myocardial infarction. An open randomized study "Prague-5". Int Heart J. 2008 Nov;49(6):653-9. doi: 10.1536/ihj.49.653.

Reference Type BACKGROUND
PMID: 19075481 (View on PubMed)

Kotowycz MA, Cosman TL, Tartaglia C, Afzal R, Syal RP, Natarajan MK. Safety and feasibility of early hospital discharge in ST-segment elevation myocardial infarction--a prospective and randomized trial in low-risk primary percutaneous coronary intervention patients (the Safe-Depart Trial). Am Heart J. 2010 Jan;159(1):117.e1-6. doi: 10.1016/j.ahj.2009.10.024.

Reference Type BACKGROUND
PMID: 20102876 (View on PubMed)

Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001 Aug 8;286(6):708-13. doi: 10.1001/jama.286.6.708.

Reference Type BACKGROUND
PMID: 11495621 (View on PubMed)

Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987 Jul;76(1):142-54. doi: 10.1161/01.cir.76.1.142.

Reference Type BACKGROUND
PMID: 3109764 (View on PubMed)

O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29;127(4):e362-425. doi: 10.1161/CIR.0b013e3182742cf6. Epub 2012 Dec 17. No abstract available.

Reference Type BACKGROUND
PMID: 23247304 (View on PubMed)

Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967 Oct;20(4):457-64. doi: 10.1016/0002-9149(67)90023-9. No abstract available.

Reference Type BACKGROUND
PMID: 6059183 (View on PubMed)

Satilmisoglu MH, Gorgulu S, Aksu HU, Aksu H, Ertas G, Tasbulak O, Buturak A, Kalkan AK, Degirmencioglu A, Koroglu B, Tusun E, Murat A, Oz A. Safety of Early Discharge After Primary Percutaneous Coronary Intervention. Am J Cardiol. 2016 Jun 15;117(12):1911-6. doi: 10.1016/j.amjcard.2016.03.039. Epub 2016 Apr 6.

Reference Type DERIVED
PMID: 27156829 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

the EDAP PCI trial

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Resistance STEMI Study
NCT03439150 TERMINATED NA
Cohort of STEMI Patients
NCT02822638 COMPLETED